The pharmacoeconomic value of controlled-uelease dosage forms

Journal of Controlled Release

Volumn 48, Issue 2-3, 1997, Pages 237-242

  Saks, Samuel R ^a   Gardner, Laura B ^b  

^a ALZA CORPORATION   (United States)

^b Axiomedics Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM; MORPHINE; NIFEDIPINE; PROGESTERONE;

ARTICLE; CONTROLLED RELEASE FORMULATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSAGE FORM; DRUG MONITORING; HEALTH CARE INDUSTRY; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030865392     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00037-0     Document Type: Article

References (14)

1. D.E. Hilleman, S.M. Mohiuddin, B.D. Lucas Jr., B. Shinn, G.N. Elsasser, Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension, Clin. Ther. 15(6) (1993) 1002-1010.
2. M.P. Cramer, S.R. Saks, Translating safety, efficacy and compliance into economic value for controlled release dosage forms, PharmacoEconomics 5(6) (1994) 482-504.
3. T.L. Skaer, D.A. Sclar, L.M. Robison, D.J. Markowski, J.K. Won, Effect of pharmaceutical formulation for diltiazem on health care expenditures for hypertension, Clin. Ther. 15(5) (1993) 905-911.
4. T.L. Skaer, D.A. Sclar, D.J. Markowski, J.K. Won, Utility of a sustained-release formulation for antihypertensive therapy, J. Hum. Hypertens. 7(5) (1993) 519-522.
5. B.R. Goughnour, W.W. Arkinstall, Potential cost-avoidance with oral extended-release morphine sulphate tablets versus morphine sulphate solution, Am. J. Hosp. Pharm. 48(1) (1991) 101-104.
6. B. Ferrell, C. Wisdom, C. Wenzl, J. Brown, Effects of controlled-released morphine on quality of life for cancer pain, Oncol. Nursing Forum 16(4) (1989) 521-526.
7. A.N. Tosteson, Hormone replacement therapy: benefit, risk and cost considerations, J. Clin. Pharmacol. 34(7) (1994) 719-722.
8. R. Whittington, D. Faulds, Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital oestrogen deficiency, PharmacoEconomics 5(5) (1994) 419-445.
9. R. Whittington, D. Faulds, Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease, PharmacoEconomics 5(6) (1994) 513-554.
10. Anonymous, (1995) Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Washington, DC: Office of Technology Assessment, Congress of the United States.
11. R.M. Caputo, J.T. Benson, E. McClellan, Intravaginal maximal electrical stimulation in the treatment of urinary incontinence, J. Reprod. Med. 38(9) (1993) 667-671.
12. M.J. Borrie, H.A. Davidson, Incontinence in institutions: costs and contributing factors, Can. Med. Assoc. J. 147(3) (1992) 322-328.
13. K.B. Weiss, S.D. Sullivan, The economic costs of asthma, PharmacoEconomics 4(1) (1993) 14-30.
14. National Asthma Education Program Expert Panel, (1991) Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 91-3042. Bethesda, MD: U.S. Department of Health and Human Services.